Lars C. Borris

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman et al. · New England Journal of Medicine · 2008 · 1.4K citations · Full text

Medicine, Orthopaedic Surgery, Pharmacology +15

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

Michael R. Lassen, Walter Ageno, Lars C. Borris et al. · New England Journal of Medicine · 2008 · 1.3K citations · Full text

Medicine, Pharmacotherapy, Surgery +17

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement

Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl et al. · Circulation · 2006 · 332 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement

Bengt I. Eriksson, Lars C. Borris, O.E. Dahl et al. · Journal of Thrombosis and Haemostasis · 2005 · 300 citations · Full text

Medicine, Orthopedic Surgery, Pharmacology +17

Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

Lars C. Borris, Ola E. Dahl, Sylvia Haas et al. · Thrombosis and Haemostasis · 2008 · 271 citations

Medicine, Pharmacokinetics, Pharmacology +17